Cargando…

Testing for ROS1 in non-small cell lung cancer: a review with recommendations

Rearrangements of the ROS1 gene occur in 1–2 % of non-small cell lung cancers (NSCLCs). Crizotinib, a highly effective inhibitor of ROS1 kinase activity, is now FDA-approved for the treatment of patients with advanced ROS1-positive NSCLC. Consequently, focus on ROS1 testing is growing. Most laborato...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bubendorf, Lukas, Büttner, Reinhard, Al-Dayel, Fouad, Dietel, Manfred, Elmberger, Göran, Kerr, Keith, López-Ríos, Fernando, Marchetti, Antonio, Öz, Büge, Pauwels, Patrick, Penault-Llorca, Frédérique, Rossi, Giulio, Ryška, Aleš, Thunnissen, Erik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2016
Materias:	Review and Perspectives
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5082594/ https://www.ncbi.nlm.nih.gov/pubmed/27535289 http://dx.doi.org/10.1007/s00428-016-2000-3

Ejemplares similares

EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations
por: Thunnissen, Erik, et al.
Publicado: (2012)

Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert Group
por: Dietel, Manfred, et al.
Publicado: (2016)

Expert opinion on NSCLC small specimen biomarker testing — Part 1: Tissue collection and management
por: Penault-Llorca, Frédérique, et al.
Publicado: (2022)

Expert opinion on NSCLC small specimen biomarker testing — Part 2: Analysis, reporting, and quality assessment
por: Penault-Llorca, Frédérique, et al.
Publicado: (2022)

Implementing TMB measurement in clinical practice: considerations on assay requirements
por: Büttner, Reinhard, et al.
Publicado: (2019)

Comparison of Different ROS1 Immunohistochemistry Clones and Consistency with Fluorescence In Situ Hybridization Results in Non-Small Cell Lung Carcinoma
por: Dülger, Onur, et al.
Publicado: (2023)

NSCLC molecular testing in Central and Eastern European countries
por: Ryska, Ales, et al.
Publicado: (2018)

Sensitive detection methods are key to identify secondary EGFR c.2369C>T p.(Thr790Met) in non-small cell lung cancer tissue samples
por: Keppens, Cleo, et al.
Publicado: (2020)

The Relevance of External Quality Assessment for Molecular Testing for ALK Positive Non-Small Cell Lung Cancer: Results from Two Pilot Rounds Show Room for Optimization
por: Tembuyser, Lien, et al.
Publicado: (2014)

Comparison of different commercial kits for HER2 testing in breast cancer: looking for the accurate cutoff for amplification
por: Cayre, Anne, et al.
Publicado: (2007)

aHIF but not HIF-1α transcript is a poor prognostic marker in human breast cancer
por: Cayre, Anne, et al.
Publicado: (2003)

Testing algorithm for identification of patients with TRK fusion cancer
por: Penault-Llorca, Frédérique, et al.
Publicado: (2019)

HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing
por: Rüschoff, Josef, et al.
Publicado: (2010)

From Targeting Somatic Mutations to Finding Inherited Cancer Predispositions: The Other Side of the Coin
por: Pujol, Pascal, et al.
Publicado: (2019)

Editorial: Liquid biopsy—A great hope or just hype?
por: Ryška, Aleš
Publicado: (2023)

Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study
por: van de Vijver, Marc, et al.
Publicado: (2007)

P-gp expression in brown trout erythrocytes: evidence of a detoxification mechanism in fish erythrocytes
por: Valton, Emeline, et al.
Publicado: (2013)

Spinal Cord Glioneuronal Tumor with Rosetted Neuropil-Like Islands in Pediatric Age Group
por: Comunoglu, Nil, et al.
Publicado: (2014)

Nonsmall cell lung carcinoma: diagnostic difficulties in small biopsies and cytological specimens: Number 2 in the Series “Pathology for the clinician” Edited by Peter Dorfmüller and Alberto Cavazza
por: Bubendorf, Lukas, et al.
Publicado: (2017)

Circulating proteins as predictive and prognostic biomarkers in breast cancer
por: Veyssière, Hugo, et al.
Publicado: (2022)

PD-L1 immunohistochemistry in non-small-cell lung cancer: unraveling differences in staining concordance and interpretation
por: Keppens, Cleo, et al.
Publicado: (2020)

Mini-P-gp and P-gp Co-Expression in Brown Trout Erythrocytes: A Prospective Blood Biomarker of Aquatic Pollution
por: Valton, Emeline, et al.
Publicado: (2015)

Breaking down the Contradictory Roles of Histone Deacetylase SIRT1 in Human Breast Cancer
por: Rifaï, Khaldoun, et al.
Publicado: (2018)

Co-targeting EGFR and mTOR with gefitinib and everolimus in triple-negative breast cancer cells
por: El Guerrab, Abderrahim, et al.
Publicado: (2020)

Physical basis of the ‘magnification rule’ for standardized Immunohistochemical scoring of HER2 in breast and gastric cancer
por: Scheel, Andreas H., et al.
Publicado: (2018)

The Applicability of Haarlem Integrated Diagnostic System in Diffuse Glial Tumors and Molecular Methods Affecting Prognosis
por: Kaya Terzi, Neslihan, et al.
Publicado: (2019)

The Place and Prognostic Value of TERT Promoter Mutation in Molecular Classification in Grade II-III Glial Tumors and Primary Glioblastomas
por: Kaya Terzi, Neslihan, et al.
Publicado: (2022)

Interest and Limits of [(18)F]ML-10 PET Imaging for Early Detection of Response to Conventional Chemotherapy
por: Jouberton, Elodie, et al.
Publicado: (2021)

Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer
por: Guerrab, Abderrahim El, et al.
Publicado: (2016)

PARP Inhibitors: A Major Therapeutic Option in Endocrine-Receptor Positive Breast Cancers
por: Collet, Laetitia, et al.
Publicado: (2022)

Development of automated brightfield double In Situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence In Situ hybridization (FISH)
por: Nitta, Hiroaki, et al.
Publicado: (2008)

Phosphorylated IκBα Predicts Poor Prognosis in Activated B-Cell Lymphoma and Its Inhibition with Thymoquinone Induces Apoptosis via ROS Release
por: Hussain, Azhar R., et al.
Publicado: (2013)

Identifying the Steps Required to Effectively Implement Next-Generation Sequencing in Oncology at a National Level in Europe
por: Horgan, Denis, et al.
Publicado: (2022)

Identification of miR-10b, miR-26a, miR-146a and miR-153 as potential triple-negative breast cancer biomarkers
por: Fkih M’hamed, Insaf, et al.
Publicado: (2015)

SIRT1-dependent epigenetic regulation of H3 and H4 histone acetylation in human breast cancer
por: Rifaï, Khaldoun, et al.
Publicado: (2018)

Dual SIRT1 expression patterns strongly suggests its bivalent role in human breast cancer
por: Rifaï, Khaldoun, et al.
Publicado: (2017)

The New Synthetic Serum-Free Medium OptiPASS Promotes High Proliferation and Drug Efficacy Prediction on Spheroids from MDA-MB-231 and SUM1315 Triple-Negative Breast Cancer Cell Lines
por: Dubois, Clémence, et al.
Publicado: (2019)

Why is appropriate healthcare inaccessible for many European breast cancer patients? – The EBCC 12 manifesto
por: Cardoso, Fatima, et al.
Publicado: (2021)

Chemical biology fluorescent tools for in vitro investigation of the multidrug resistant P-glycoprotein (P-gp) expression in tumor cells
por: Daumar, Pierre, et al.
Publicado: (2023)

Cellular Expression of Cyclooxygenase, Aromatase, Adipokines, Inflammation and Cell Proliferation Markers in Breast Cancer Specimen
por: Basu, Samar, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_di045ge7ue7abk8bh7k7b179b8